Evidence map›Paper›PMID 30643127›Full record

ArticleNature communications2019

Anti-CRISPR-mediated control of gene editing and synthetic circuits in eukaryotic cells.

Muneaki Nakamura, Prashanth Srinivasan, Michael Chavez, Matthew A Carter, Antonia A Dominguez, Marie La Russa, Matthew B Lau, Timothy R Abbott, Xiaoshu Xu, Dehua Zhao and 5 more

Abstract readVideo-Audio Media
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 81 papers.

0numbers the graph read from it
0cells of the map it votes in
81citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

81 citing papers in PubMed.

  1. Article
  2. Review
  3. Ratiometric transcriptional activation by protein degradation.bioRxiv : the preprint server for biology · 2026
    Article
  4. Article
  5. Review
  6. Article
  7. Bacteria as living biosensors for DNA.Nature reviews bioengineering · 2026
    Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Protective antigen-mediated delivery of an anti-CRISPR protein for precision genome editing.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  13. Article
  14. Mechanism of Cas9 inhibition by AcrIIA11.Nucleic acids research · 2025
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

21 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors.

Muneaki NakamuraDepartment of Bioengineering, Stanford University, Stanford, CA, 94305, USA.
Prashanth SrinivasanDepartment of Bioengineering, Stanford University, Stanford, CA, 94305, USA.
Michael ChavezDepartment of Bioengineering, Stanford University, Stanford, CA, 94305, USA.
Matthew A CarterDepartment of Bioengineering, Stanford University, Stanford, CA, 94305, USA.
Antonia A DominguezDepartment of Bioengineering, Stanford University, Stanford, CA, 94305, USA.
Marie La RussaDepartment of Bioengineering, Stanford University, Stanford, CA, 94305, USA.
Matthew B LauDepartment of Bioengineering, Stanford University, Stanford, CA, 94305, USA.
Timothy R AbbottDepartment of Bioengineering, Stanford University, Stanford, CA, 94305, USA.ORCID http://orcid.org/0000-0001-7404-811X
Xiaoshu XuDepartment of Bioengineering, Stanford University, Stanford, CA, 94305, USA.
Dehua ZhaoDepartment of Bioengineering, Stanford University, Stanford, CA, 94305, USA.
Yuchen GaoDepartment of Bioengineering, Stanford University, Stanford, CA, 94305, USA.
Nathan H KipnissDepartment of Bioengineering, Stanford University, Stanford, CA, 94305, USA.ORCID http://orcid.org/0000-0001-9864-942X
Christina D SmolkeDepartment of Bioengineering, Stanford University, Stanford, CA, 94305, USA.
Joseph Bondy-DenomyDepartment of Microbiology and Immunology, University of California, San Francisco, CA, 94158, USA.
Lei S QiDepartment of Bioengineering, Stanford University, Stanford, CA, 94305, USA. stanley.qi@stanford.edu.ORCID http://orcid.org/0000-0002-3965-3223

Funding

PREDOCTORAL TRAINING IN BIOMEDICAL SCIENCEST32GM008568 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ANSEL, KARL MARK · 1995 to 2019
$6.3M
NIGMS NIH HHS T32 GM008568
6 · The paper itself

Abstract

Repurposed CRISPR-Cas molecules provide a useful tool set for broad applications of genomic editing and regulation of gene expression in prokaryotes and eukaryotes. Recent discovery of phage-derived proteins, anti-CRISPRs, which serve to abrogate natural CRISPR anti-phage activity, potentially expands the ability to build synthetic CRISPR-mediated circuits. Here, we characterize a panel of anti-CRISPR molecules for expanded applications to counteract CRISPR-mediated gene activation and repression of reporter and endogenous genes in various cell types. We demonstrate that cells pre-engineered with anti-CRISPR molecules become resistant to gene editing, thus providing a means to generate "write-protected" cells that prevent future gene editing. We further show that anti-CRISPRs can be used to control CRISPR-based gene regulation circuits, including implementation of a pulse generator circuit in mammalian cells. Our work suggests that anti-CRISPR proteins should serve as widely applicable tools for synthetic systems regulating the behavior of eukaryotic cells.

Indexed as

BacteriophagesCell Culture TechniquesClustered Regularly Interspaced Short Palindromic RepeatsCRISPR-Cas SystemsEukaryotic CellsGene EditingGene Regulatory NetworksGenetic VectorsHEK293 CellsHumansInduced Pluripotent Stem CellsIntravital MicroscopyLentivirusMicroscopy, FluorescenceTime-Lapse ImagingTransduction, Genetic

Identifiers

PMID30643127
PMCPMC6331597

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.